PDL Biopharma Profit Margin

PDL Biopharma (PDLI) currently reports a profit margin of -2524.15% as of September 2020. That compares with 0.72% in the prior-year period — down 352640.2% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore PDL Biopharma's profit margin history and peer comparisons.

PDL Biopharma's profit margin decreased from 0.72% to -2524.15% — a 352640.2% year-over-year decrease (period ending September 2020). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

PDL Biopharma's profit margin of -2524.15% is lower than the Healthcare sector average of 13.89%. That is roughly 18268.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but PDL Biopharma's current -2524.15% should be judged against Healthcare norms (sector average: 13.89%) and against PDLI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -2524.15%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for PDL Biopharma, and consider following PDLI for alerts when major investors trade the stock.